Cantor Fitzgerald Issues Negative Estimate for RARE Earnings

Key Points

• Cantor Fitzgerald has revised its FY2025 earnings per share estimate for Ultragenyx Pharmaceutical to ($5.19), slightly lower than its previous estimate of ($5.15), maintaining an "Overweight" rating with a target price of $105.00.
• Recent analyst reports show mixed opinions, with HC Wainwright upgrading the stock to "buy" at $80.00, while Morgan Stanley reduced their target from $65.00 to $55.00.
• Ultragenyx reported a quarterly EPS of ($1.17), which surpassed the consensus estimate of ($1.27), alongside a revenue increase of 13.2% year-over-year, totaling $166.5 million.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Stock analysts at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for Ultragenyx Pharmaceutical in a note issued to investors on Wednesday, August 6th. Cantor Fitzgerald analyst K. Kluska now expects that the biopharmaceutical company will earn ($5.19) per share for the year, down from their previous estimate of ($5.15). Cantor Fitzgerald has a "Overweight" rating and a $105.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share. Cantor Fitzgerald also issued estimates for Ultragenyx Pharmaceutical's FY2026 earnings at ($3.21) EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, beating the consensus estimate of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The firm had revenue of $166.50 million during the quarter, compared to the consensus estimate of $161.37 million. During the same period last year, the firm posted ($1.52) EPS. The firm's revenue for the quarter was up 13.2% on a year-over-year basis.

A number of other equities research analysts have also recently commented on the company. Canaccord Genuity Group lowered their target price on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating on the stock in a report on Friday. Wedbush decreased their price objective on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating on the stock in a research note on Monday, July 14th. Guggenheim reiterated a "buy" rating and set a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. William Blair initiated coverage on shares of Ultragenyx Pharmaceutical in a report on Wednesday, May 28th. They issued an "outperform" rating and a $65.00 target price on the stock. Finally, Wells Fargo & Company lowered their price target on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating for the company in a report on Thursday, July 10th. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $81.50.

Ultragenyx Pharmaceutical Stock Up 1.7%

Shares of RARE traded up $0.46 during mid-day trading on Friday, reaching $27.85. 630,229 shares of the company's stock were exchanged, compared to its average volume of 1,291,496. Ultragenyx Pharmaceutical has a 52-week low of $25.81 and a 52-week high of $60.37. The company has a market cap of $2.68 billion, a price-to-earnings ratio of -5.04 and a beta of 0.25. The company has a 50-day simple moving average of $33.15 and a two-hundred day simple moving average of $36.56.

Insider Buying and Selling

In other news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the business's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $37.39, for a total transaction of $89,922.95. Following the completion of the sale, the director directly owned 15,344 shares of the company's stock, valued at $573,712.16. The trade was a 13.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 5.50% of the company's stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc raised its holdings in shares of Ultragenyx Pharmaceutical by 21.2% in the 2nd quarter. Legal & General Group Plc now owns 313,804 shares of the biopharmaceutical company's stock worth $11,410,000 after purchasing an additional 54,837 shares during the period. DNB Asset Management AS increased its position in Ultragenyx Pharmaceutical by 3.2% during the 2nd quarter. DNB Asset Management AS now owns 14,720 shares of the biopharmaceutical company's stock worth $535,000 after purchasing an additional 452 shares in the last quarter. Entropy Technologies LP raised its holdings in Ultragenyx Pharmaceutical by 50.2% in the second quarter. Entropy Technologies LP now owns 11,336 shares of the biopharmaceutical company's stock valued at $412,000 after buying an additional 3,787 shares during the period. Knott David M Jr lifted its position in Ultragenyx Pharmaceutical by 8.3% during the second quarter. Knott David M Jr now owns 52,000 shares of the biopharmaceutical company's stock valued at $1,891,000 after buying an additional 4,000 shares in the last quarter. Finally, Creative Planning acquired a new position in Ultragenyx Pharmaceutical during the second quarter valued at approximately $454,000. Hedge funds and other institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.